PTCT logo

PTCT
PTC Therapeutics Inc

4,287
Mkt Cap
$5.93B
Volume
843,494.00
52W High
$87.50
52W Low
$43.18
PE Ratio
-30.52
PTCT Fundamentals
Price
$71.47
Prev Close
$72.72
Open
$72.45
50D MA
$68.56
Beta
1.21
Avg. Volume
1.08M
EPS (Annual)
$7.78
P/B
-32.82
Rev/Employee
$1.75M
$5,161.47
Loading...
Loading...
News
all
press releases
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·10d ago
News Placeholder
More News
News Placeholder
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results PR Newswire...
PR Newswire·10d ago
News Placeholder
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
Zacks·11d ago
News Placeholder
Horizon Investments LLC Takes $3.06 Million Position in PTC Therapeutics, Inc. $PTCT
Horizon Investments LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 40,333 shares of the biopharmaceutical company's stock, va...
MarketBeat·12d ago
News Placeholder
Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·13d ago
News Placeholder
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics to Participate in Upcoming Investor Conferences PR Newswire WARREN, N.J., May 4, 2026 WARREN, N.J., May 4, 2026...
PR Newswire·13d ago
News Placeholder
Vanguard Group Inc. Purchases 514,204 Shares of PTC Therapeutics, Inc. $PTCT
Vanguard Group Inc. raised its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 6.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,803,203 shares of th...
MarketBeat·13d ago
News Placeholder
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago
News Placeholder
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday
PTC Therapeutics (NASDAQ:PTCT) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·18d ago
<
1
2
...
>

Latest PTCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.